Sareum confident despite recent setbacks
16th Dec 2022 16:55
(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.
Read moreSareum progresses Covid-19 and autoimmune treatment candidate
16th Mar 2022 14:21
(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human trials on Wednesday.
Read moreSareum expects FY losses to widen on higher R&D costs, supply delays
19th Aug 2021 07:41
(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.
Read moreSareum positive on SRA737 outlook after Sierra call
6th Aug 2021 15:00
(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced global in-licensing agreement with AstraZeneca for AZD5153 with investors, which is a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.
Read moreSareum releases 'encouraging' results from Covid-19 research
1st Jul 2021 11:18
(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.
Read moreSareum's pre-clinical development of SDC-1801 delayed by Covid-19
25th May 2021 10:56
(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801 drug candidate for autoimmune disease.
Read moreSareum gets approval for US patent application
7th Jan 2021 12:52
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office has now formally approved its patent application, number 16/351,620.
Read moreSareum Holdings secures grant for Covid-19 treatment project
3rd Dec 2020 12:19
(Sharecast News) - Specialist drug development company Sareum Holdings announced on Thursday that the grant offer letter from UK Research and Innovation (UKRI) had now been received and approved.
Read moreSareum to get US patent on SDC-1802 programme
8th Oct 2020 15:50
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention associated with its proprietary 'SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme'.
Read moreSareum Holdings upbeat ahead of cancer research presentation
27th Sep 2019 09:10
(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Friday that it will present new preclinical data from its 'SDC-1802 TYK2/JAK1' inhibitor cancer research programme at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) international conference, in late October in Boston, Massachusetts.
Read moreSareum Holdings expects broadly flat interim losses
27th Aug 2019 08:35
(Sharecast News) - Drug developer Sareum expects interim losses to be broadly flat year-on-year as it continues to focus on the development of multiple treatments for cancer and autoimmune diseases.
Read moreSareum's loss widens as development costs expand
4th Mar 2019 08:26
(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.
Read moreSareum flags potentially significant findings for SRA737
28th Feb 2019 14:33
(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.
Read moreSareum raises £850,000 to fund cancer inhibitor
26th Oct 2018 08:38
(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.
Read moreSareum Holdings selects cancer therapy development candidate
26th Sep 2018 15:20
(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.
Read more